Clinical Trial Update: Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients [Phase 2]

View source ↗

Summary

This document notes that a Phase 2 trial investigating nivolumab with the FOLFOX regimen after chemoradiation in rectal cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)
• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Baruch Brenner | Conditions: Rectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING